Actively Recruiting
Haploidentical Hematopoietic Stem Cell Transplantation With Early Antithymocyte Globulin and Low Dose Post-transplant Cyclophosphamide
Led by Samsung Medical Center · Updated on 2024-12-03
20
Participants Needed
1
Research Sites
25 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are studying patients undergoing haploidentical hematopoietic stem cell transplantation (haplo-HCT) to evaluate the effects of early antithymocyte globulin and low-dose post-transplant cyclophosphamide (ATG/LD-PTCy). This observational study aims to define the best approach for patients lacking a matched donor, focusing on outcomes after this specific conditioning regimen at a single center. Participants receive haploidentical stem cell transplants with conditioning using early ATG and low-dose cyclophosphamide after transplant. The study specifically monitors patients treated at the pediatrics department of Samsung Medical Center, following a standardized treatment plan involving ATG and LD-PTCy. During the study, researchers track key outcomes such as engraftment rate and time, acute and chronic graft-versus-host disease (GVHD), and rates of complications like cytomegalovirus infection and hemorrhagic cystitis. These outcomes are measured at various time points up to two years post-transplant. Participant involvement includes careful monitoring of blood counts and clinical status, with a total follow-up period extending to two years after transplantation.
CONDITIONS
Brief Title
Haploidentical Hematopoietic Stem Cell Transplantation With Early ATG and Low Dose Post-transplant Cyclophosphamide
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients undergoing haploidentical hematopoietic stem cell transplantation with ATG and low-dose post-transplant cyclophosphamide conditioning at the department of pediatrics, Samsung Medical Center.
You will not qualify if you...
- Patients or their legal representatives who do not consent or are unable to give written consent.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - From transplantation up to 28 days
Participants undergo haploidentical hematopoietic stem cell transplantation with early antithymocyte globulin and low dose post-transplant cyclophosphamide.
Regular visits during initial 28 days post-transplant
Duration - Up to 2 years after transplantation
Participants are monitored for acute and chronic graft-versus-host disease, cytomegalovirus infection, and other post-transplant complications.
Periodic follow-up visits over 2 years
Trial Site Locations
Total: 1 location
1
Samsung Medical Center
Seoul, South Korea
Actively Recruiting
Research Team
H
Hee Young Ju
M
Min Suk Rheu
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here